ClinicalTrials.gg
CompletedNCT04597450Updated Mar 24, 2023

Lu AG06466 in Participants With Post Traumatic Stress Disorder (PTSD)

A Phase 1 interventional study of Lu AG06466 and Placebo in PTSD, sponsored by H. Lundbeck A/S. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2023-03-24.

Sponsored by H. Lundbeck A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was Feb 2023, 3 years 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
35
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States — 340 open to participants now, 403 under way, 18 of them phase 3. Stress Disorders, Post-Traumatic · United States.

Enrollment
1,039th of 1,491
35 · median 65
Started
2020
with 69 others
Phase 1
97 of 1,664
18 open now
Registered
1,076th of 1,664
by date

Among the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, this one is the 1,039th largest by enrollment of the 1,491 interventional ones that give a count, is one of 70 that started in 2020, is one of 97 in phase 1, and was the 1,076th registered.

Stress Disorders, Post-Traumatic

2,689 studies on the registry are indexed under Stress Disorders, Post-Traumatic; 605 are open to participants now.

Browse Stress Disorders, Post-Traumatic studies →

Open to participants now

340 of the 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States are open now. Recruiting first, the newest first:

335 more — sign in →

All 340 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 416 Stress Disorders, Post-Traumatic studies recruiting now, 188 (45%) set no upper age limit and 202 (49%) stop at 75 or younger; 62 take children under 18; 88 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,664 studies in Stress Disorders, Post-Traumatic with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to investigate the effect of Lu AG06466 after multiple doses of 30 milligrams (mg) in participants with PTSD.

Read the detailed description

The crossover study consists of two treatment periods of 15 days duration. On Day -1 or Day 1 of Treatment Period 1, eligible participants will be randomized (1:1) to a sequence of treatments (either Lu AG06466-placebo or placebo-Lu AG06466) with 15 participants are planned per sequence. Each treatment period will be separated by a washout period of ≥7 and ≤14 days.

03

Conditions studied

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The participant has PTSD, diagnosed according to Diagnostic and Statistical Manual Diploma in Social Medicine-5 (), and confirmed by the Mini International Neuropsychiatric Interview (MINI).
  • The participant has a Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) total score ≥28 at screening and baseline.
  • The participant has alterations in arousal and reactivity, confirmed on CAPS-5.
  • The participant has ongoing sleep disturbances, confirmed on CAPS-5.
  • The participant is willing to discontinue all prohibited medications during the study and to complete a of psychotropic medication during the washout period.
  • The participant does not have any magnetic resonance imaging (MRI) .

Exclusion criteria

Exclusion Criteria:

  • The index traumatic event that led to development of PTSD took place >15 years or \<6 months before screening.

Other inclusion and exclusion criteria may apply.

Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Lu AG06466

    Drug: Lu AG06466

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • DrugABX-1431Studies of ABX-1431ABX-1431 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Lu AG06466 - 30 mg/day, capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period

  • DrugPlacebo

    Placebo - capsules, orally, once daily, one capsule will be taken daily for 15 days per treatment period

06

What researchers measure

Primary outcomes

  1. Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Facial Affect Recognition Task

    fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Facial Affect Recognition Task

    Time frame: Day 15

  2. Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Threat Processing Task

    fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Threat Processing Task

    Time frame: Day 15

  3. Functional Magnetic Resonance Imaging (fMRI) Data: Mean Blood Oxygen Level Dependent (BOLD) Percent Signal Change During Card Guessing Task

    fMRI parameter estimates (β-contrasts) will be extracted per participant/treatment period from task-related regions of interest (ROIs) under task-specific contrast, Card Guessing Task

    Time frame: Day 15

  4. Skin Conductance Response (SCR) During fMRI Tasks

    SCR in micro-Siemens

    Time frame: Day 15

  5. Skin Conductance Response (SCR) During the Threat Processing Task

    SCR in micro-Siemens

    Time frame: Day 14

  6. Behavioural Measures During fMRI Tasks

    Behavioural Response: behavioural measures rated on a 3-point scale

    Time frame: Day 15

  7. Behavioural Measures During the Threat Processing Task

    Behavioural Response: behavioural measures rated on a 3-point scale

    Time frame: Day 14

  8. Sleep, Polysomnography (PSG) Parameters: Total Sleep Time (TST)

    TST in minutes

    Time frame: Day 12-13

  9. Sleep, Polysomnography (PSG) Parameters: Sleep Efficiency (SE)

    SE in percent

    Time frame: Day 12-13

  10. Sleep, Polysomnography (PSG) Parameters: Wake-Time After Sleep-Onset (WASO)

    WASO in minutes

    Time frame: Day 12-13

  11. Sleep, Polysomnography (PSG) Parameters: Sleep Onset Latency (SOL)

    SOL in minutes

    Time frame: Day 12-13

07

Study locations

1 site
  • Collaborative NeuroScience Network LLC
    Long Beach, California 90806, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Feb 2023, 28 months.

Of 52 phase 1 interventional studies under Stress Disorders, Post-Traumatic, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's 28 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2020
First posted
Oct 22, 2020
StartActual
Sep 30, 2020
Primary completionActual
Feb 13, 2023
CompletionActual
Feb 13, 2023
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04597450
Lead sponsor
H. Lundbeck A/S
Responsible party
Sponsor
First posted
Oct 22, 2020
Start date
Sep 30, 2020
Primary completion
Feb 13, 2023
Completion
Feb 13, 2023
Last update
Mar 24, 2023

Study contacts

Email contact via H. Lundbeck A/S
study director · LundbeckClinicalTrials@Lundbeck.com

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: ABX-1431

Start the discussion